Summary: A new study reveals that, under stress, the brain produces its own cannabinoid molecules—chemicals that act on the same receptors as THC from cannabis—to help reduce stress signals and promote adaptive responses.
These endocannabinoids are produced in the amygdala and act to suppress stress-related input coming from the ventral hippocampus, a brain region involved in memory and emotion. The findings suggest an innate neural mechanism for coping with stress and highlight the endocannabinoid system as a potential therapeutic target for stress-related psychiatric conditions.
Disruption of this signaling pathway could increase susceptibility to disorders triggered or aggravated by stress.
Key Facts:
- The amygdala releases endogenous cannabinoids that engage the same receptors affected by THC, helping to reduce stress responses.
- Removing the primary cannabinoid receptor (CB1) at hippocampal–amygdala synapses in mice impaired their stress coping and reduced motivated, reward-seeking behavior.
- The research reinforces the endocannabinoid system’s promise as a drug-development target for treating stress-related disorders such as anxiety, depression and PTSD.
Source: Northwestern University
When you experience stress, your brain may release its own cannabinoid chemicals to help calm the body, activating the same receptors that respond to THC.
Until now, the precise patterns of brain activity and the neural circuits governed by these brain-derived cannabinoids were not fully understood.
A new study from Northwestern Medicine using mouse models shows that the basolateral amygdala, a central hub for emotion processing, releases endocannabinoid molecules during stress. These molecules act locally to dampen stress signals coming from the ventral hippocampus, a region tied to memory and emotional regulation. The results support the idea that endocannabinoid release is a native coping mechanism the brain uses to counter stress.
Stress exposure increases the risk of developing or worsening psychiatric illnesses, including generalized anxiety, major depression and post-traumatic stress disorder (PTSD).
“Understanding how the brain adapts to stress at molecular, cellular and circuit levels can reveal how stress transitions into mood disorders and point to new therapeutic strategies,” said corresponding author Dr. Sachi Patel, chair of psychiatry and behavioral sciences at Northwestern University Feinberg School of Medicine and a Northwestern Medicine psychiatrist.
The researchers caution that while these findings suggest that impairments in endocannabinoid signaling could raise vulnerability to stress-related psychiatric disorders, translating this link to humans will require further study.
The study is scheduled for publication Sept. 12 in Cell Reports.
To measure endocannabinoid release with high spatial and temporal resolution, the team used a novel protein sensor capable of detecting these molecules at specific synapses in real time. The sensor revealed that particular high-frequency firing patterns in the amygdala generate endocannabinoid release and that several distinct stressors trigger this release in mice.
When researchers genetically removed cannabinoid receptor type 1 (CB1) at ventral hippocampus–basolateral amygdala (vHPC–BLA) synapses, mice showed poorer stress coping and motivational deficits. Specifically, mice lacking CB1 signaling at these synapses displayed more passive, immobile responses during stress tests and showed reduced preference for sweetened sucrose solution after stress—an indicator related to anhedonia, or diminished pleasure, commonly seen in depression and PTSD.
The endocannabinoid system is recognized as a major neuromodulatory pathway that controls glutamate release across limbic circuits, thereby shaping stress responsiveness and behavioral adaptation. These new data identify the in vivo triggers for endocannabinoid release at limbic synapses and demonstrate that vHPC–BLA endocannabinoid signaling actively counteracts adverse behavioral consequences of stress.
“A logical next step is to explore whether boosting endogenous cannabinoid levels could serve as a therapeutic strategy for stress-related disorders,” said Patel, who is also the Lizzie Gilman Professor of Psychiatry and Behavioral Sciences. “There are ongoing clinical trials examining related approaches that may help answer this question.”
Other Northwestern authors on the paper include Farhana Yasmin, Amanda Morgan and Keenan Johnson.
The article is titled “Endocannabinoid release at ventral hippocampal–amygdala synapses regulates stress-induced behavioral adaptation.”
Funding: This research was supported by National Institutes of Health grants F31MH126I460, MH107435 and MH119817 from the National Institute of Mental Health and grant AA9013514 from the National Institute on Alcohol Abuse and Alcoholism, Integrative Neuroscience Initiative on Alcoholism.
About this stress and neuroscience research news
Author: Marla Paul
Source: Northwestern University
Contact: Marla Paul – Northwestern University
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Endocannabinoid release at ventral hippocampal-amygdala synapses regulates stress-induced behavioral adaptation” by Sachi Patel et al. Cell Reports
Abstract
Endocannabinoid release at ventral hippocampal–amygdala synapses regulates stress-induced behavioral adaptation
Highlights
- Basolateral amygdala (BLA) activity drives endocannabinoid release at vHPC–BLA synapses.
- Active stress-coping behavior recruits vHPC–BLA endocannabinoid signaling.
- Deletion of CB1 receptors at vHPC–BLA synapses worsens stress-induced avoidance and anhedonia-like behaviors.
Summary
The endocannabinoid (eCB) system is a crucial regulator of glutamate transmission within limbic circuits, and it plays a major role in determining how the brain responds and adapts to stress.
The ventral hippocampus–basolateral amygdala circuit has been implicated in negative emotional states that follow stress, and it is modulated by retrograde eCB signaling.
Prior to this work, the precise mechanisms that trigger eCB release in vivo and the causal impact of vHPC–BLA eCB signaling on stress-related behavioral changes were not well defined.
Using in vivo optogenetics together with a sensitive biosensor, the investigators mapped the timing and activity patterns that produce eCB release at vHPC–BLA synapses during normal and stress conditions.
They also show that genetically removing CB1 receptors specifically at these synapses reduces active coping strategies and amplifies avoidance and anhedonia-like outcomes after stress exposure.
Together, these findings define the in vivo drivers of endocannabinoid release at limbic synapses and demonstrate that eCB signaling within the vHPC–BLA circuit mitigates detrimental behavioral effects of stress.